Could a common diabetes pill boost lung cancer treatment?

NCT ID NCT05445791

Recruiting now Disease control Sponsor: Instituto Nacional de Cancerologia de Mexico Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding metformin, a standard diabetes drug, to standard targeted therapy (tyrosine kinase inhibitors) can help people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 312 participants will receive either metformin or a placebo alongside their targeted therapy. The goal is to see if this combination delays resistance to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin (a diabetes drug) plus a tyrosine kinase inhibitor (targeted cancer pill)
What this could lead to: If it works, this could extend the time that lung cancer stays under control for people with EGFR mutations, delaying disease progression.
What could go wrong: This is a mid-stage trial; earlier studies gave mixed results. Metformin may cause gastrointestinal side effects, and the benefit may be small or absent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Locations

Instituto Nacional de Cancerologia
RECRUITING

Mexico City, 14080, Mexico

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.